Home / Going-concern warnings / CNBX Pharmaceuticals Inc.
Filed 2025-07-14 路 Form 10-Q 路 Accession 0001683168-25-005075 nano
Price before filing: $0.0006 (2025-07-11 close, split/dividend-adjusted)
Market cap at flag: $332,377 (2025-07-14) 路 Latest: $197,789 (2026-10-16)
| Window | CNBX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -33.3% | +3.4% | -36.7% | 2025-08-13 |
| 90 days | -45.0% | +6.6% | -51.6% | 2025-10-13 |
| 180 days | -33.3% | +12.1% | -45.4% | 2026-01-12 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"While the Company has incurred a net loss of $ 163,867 for the nine months ended May 31, 2025, it has incurred cumulative losses since inception of $ 25,118,267 . These conditions raise substantial doubt about the ability of the Company to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-05-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.